

### **Amendments to the Specification:**

Please amend the specification as follows:

Beginning on page 19, spanning lines 5 through 18; please replace with the following:

Thus, in one aspect, the present invention relates to proteinaceous materials for Fab1p, Vac14p, and Fig4. In addition to an entire polypeptide (SEQ ID NOS:1, 3, 5 and 7), the present invention also relates to fragments of the polypeptides that may or may not retain various of the functions described below. Fragments, including the N-terminus of the molecule may be generated by genetic engineering of translation stop sites within the coding region (discussed below). Alternatively, treatment of the STARS with proteolytic enzymes, known as proteases, can produce a variety of N-terminal, C-terminal and internal fragments. Examples of fragments may include contiguous residues of SEQ ID NOS:1, 3, 5, and 7 of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 75, 80, 85, 90, 95, 100, 200, 300, 400 or more amino acids in length. These fragments may be purified according to known methods, such as precipitation (*e.g.*, ammonium sulfate), HPLC, ion exchange chromatography, affinity chromatography (including immunoaffinity chromatography) or various size separations (sedimentation, gel electrophoresis, gel filtration).

Beginning on page 83, spanning lines 22 through 30; please replace with the following:

**Class III *vac* mutants are defective in PI3,5P2 synthesis.** Class III *vac* mutants were isolated based on their vacuole inheritance defect and found that they are defective in several processes that involve deformation of the vacuole membrane. These processes include an inability to form segregation structures (Bonangelino *et al.*, 1997), a defect in vacuole fission (Bonangelino *et al.*, 1997), and a defect in retrograde traffic from the vacuole~~57~~ vacuole. Three complementation groups with these phenotypes were identified, *fab1*, *vac7* and *vac14*. The inventor subsequently discovered that each of the corresponding proteins Fab1p, Vac7p and Vac14p, are required to maintain normal levels of PI3,5P2 (Gary *et al.*, 1998).